WO2012119781A3 - Novel lipids, phospholipids, phospholipid and lipid compositions and their use - Google Patents

Novel lipids, phospholipids, phospholipid and lipid compositions and their use Download PDF

Info

Publication number
WO2012119781A3
WO2012119781A3 PCT/EP2012/001053 EP2012001053W WO2012119781A3 WO 2012119781 A3 WO2012119781 A3 WO 2012119781A3 EP 2012001053 W EP2012001053 W EP 2012001053W WO 2012119781 A3 WO2012119781 A3 WO 2012119781A3
Authority
WO
WIPO (PCT)
Prior art keywords
phospholipid
phospholipids
lipid compositions
lipid
novel lipids
Prior art date
Application number
PCT/EP2012/001053
Other languages
French (fr)
Other versions
WO2012119781A2 (en
Inventor
Till SAXER
Andreas Zumbuehl
Bert MULLER
Illya FEDOTENKO
Margaret HOLME
Pierre-Léonard ZAFFALON
Original Assignee
University Of Geneva
University Hospitals Of Geneva
University Of Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Geneva, University Hospitals Of Geneva, University Of Basel filed Critical University Of Geneva
Publication of WO2012119781A2 publication Critical patent/WO2012119781A2/en
Publication of WO2012119781A3 publication Critical patent/WO2012119781A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a composition comprising or consisting of 1,3-diamidophospholipids or/and 1,2-diamidophospholipids or/and 2,3-diamidophospholopids or/and another lipid and preferably at least a further compound which compound is i. at least one natural lipid, ii. at least one synthetic lipid, iii. cholesterol or a cholesterol derivative or/and a surfactant, methods of making same, nanoparticles comprising same and their medical and non-medical use.
PCT/EP2012/001053 2011-03-10 2012-03-09 Novel lipids, phospholipids, phospholipid and lipid compositions and their use WO2012119781A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161451153P 2011-03-10 2011-03-10
US61/451,153 2011-03-10

Publications (2)

Publication Number Publication Date
WO2012119781A2 WO2012119781A2 (en) 2012-09-13
WO2012119781A3 true WO2012119781A3 (en) 2013-01-03

Family

ID=45922636

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2012/001053 WO2012119781A2 (en) 2011-03-10 2012-03-09 Novel lipids, phospholipids, phospholipid and lipid compositions and their use
PCT/EP2012/001052 WO2012119780A2 (en) 2011-03-10 2012-03-09 Novel lipids and novel phospholipids structures

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/001052 WO2012119780A2 (en) 2011-03-10 2012-03-09 Novel lipids and novel phospholipids structures

Country Status (1)

Country Link
WO (2) WO2012119781A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10940201B2 (en) * 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity
DE102015014912B4 (en) * 2015-11-18 2017-09-28 Urotech Gmbh Coating for a medical instrument, method for its coating and medical instrument coated with this method
CN106750450B (en) * 2016-11-07 2020-10-27 西安科技大学 Preparation method of bionic coating containing epoxy phosphorylcholine polymer and dopamine cross-linked adhesion
JP6242532B1 (en) * 2017-07-13 2017-12-06 佐々木食品工業株式会社 Novel compound, agent for preventing or treating fatty liver, blood cholesterol lowering agent, and food composition for lowering blood cholesterol
EP3520819A1 (en) 2018-01-31 2019-08-07 Universität Basel Shear stress sensitive liposomes
AU2019253085A1 (en) * 2018-04-13 2020-10-29 Acthera Therapeutics Ltd. Noble metal-coated mechanoresponsive vesicles
KR102312654B1 (en) * 2020-12-28 2021-10-15 (주)네오팜 Anti-inflammaging composition
KR102323657B1 (en) * 2021-10-06 2021-11-09 (주)네오팜 Composition for anti-inflammatory

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2515146A1 (en) * 1975-04-08 1976-10-21 Bayer Ag Hypolipemic carboxylic-amides - such as N-isovaleryl N,N'-bis-(10-undecenoyl) ethylene-diamine
WO1997038966A2 (en) * 1996-04-15 1997-10-23 Virginia Commonwealth University Cytoprotective compounds
US6168778B1 (en) * 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US20050095280A1 (en) * 2003-10-15 2005-05-05 Michalakis Savva Single-component pH-sensitive liposomes of reduced solid-to-liquid phase transition temperatures
WO2006006161A2 (en) * 2004-07-09 2006-01-19 Vascular Biogenics Ltd. Improved process for the preparation of oxidized phospholipids
US20060035977A1 (en) * 2003-02-12 2006-02-16 Gentif Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f
US20060155146A1 (en) * 2005-01-13 2006-07-13 Lenges Christian P Rheology control agents
WO2010052718A1 (en) * 2008-11-06 2010-05-14 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
WO2010071852A2 (en) * 2008-12-19 2010-06-24 University Of Florida Research Foundation, Inc. Oligonucleotide micelles
WO2010150004A1 (en) * 2009-06-22 2010-12-29 Sylentis S.A.U. Novel drugs for inhibition of gene expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4772958B2 (en) 1998-02-09 2011-09-14 ブラッコ・リサーチ・ソシエテ・アノニム Delivery towards the target of biologically active media
US7659242B2 (en) * 2004-07-19 2010-02-09 Thia Medica As Composition comprising protein material and compounds comprising non-oxidizable fatty acid entities
WO2009056955A1 (en) 2007-10-30 2009-05-07 University Of Basel Amine-bearing phospholipids (abps), their synthesis and use

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2515146A1 (en) * 1975-04-08 1976-10-21 Bayer Ag Hypolipemic carboxylic-amides - such as N-isovaleryl N,N'-bis-(10-undecenoyl) ethylene-diamine
US6168778B1 (en) * 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
WO1997038966A2 (en) * 1996-04-15 1997-10-23 Virginia Commonwealth University Cytoprotective compounds
US20060035977A1 (en) * 2003-02-12 2006-02-16 Gentif Uses of acylated aminopropanediols and sulphur and nitrogen analogues of same f
US20050095280A1 (en) * 2003-10-15 2005-05-05 Michalakis Savva Single-component pH-sensitive liposomes of reduced solid-to-liquid phase transition temperatures
WO2006006161A2 (en) * 2004-07-09 2006-01-19 Vascular Biogenics Ltd. Improved process for the preparation of oxidized phospholipids
US20060155146A1 (en) * 2005-01-13 2006-07-13 Lenges Christian P Rheology control agents
WO2010052718A1 (en) * 2008-11-06 2010-05-14 Vascular Biogenics Ltd. Oxidized lipid compounds and uses thereof
WO2010071852A2 (en) * 2008-12-19 2010-06-24 University Of Florida Research Foundation, Inc. Oligonucleotide micelles
WO2010150004A1 (en) * 2009-06-22 2010-12-29 Sylentis S.A.U. Novel drugs for inhibition of gene expression

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BERNARD A L ET AL: "Shear-induced permeation and fusion of lipid vesicles", JOURNAL OF COLLOID AND INTERFACE SCIENCE, ACADEMIC PRESS, NEW YORK, NY, US, vol. 287, no. 1, 1 July 2005 (2005-07-01), pages 298 - 306, XP004902706, ISSN: 0021-9797, DOI: 10.1016/J.JCIS.2004.12.019 *
CLARY L ET AL: "Membrane permeability and stability of liposomes made from highly fluorinated double-chain phosphocholines derived from diaminopropanol, serine or ethanolamine", BIOCHIMICA ET BIOPHYSICA ACTA - BIOMEMBRANES 19970814 NL LNKD- DOI:10.1016/S0005-2736(97)00076-X, vol. 1328, no. 1, 14 August 1997 (1997-08-14), pages 55 - 64, XP002681508, ISSN: 0005-2736 *
CLARY L ET AL: "Polymorphic phase behavior of fluorocarbon double-chain phosphocholines derived from diaminopropanol, serine and ethanolamine and long-term shelf stability of their liposomes", CHEMISTRY AND PHYSICS OF LIPIDS, LIMERICK, IR, vol. 86, no. 1, 28 March 1997 (1997-03-28), pages 21 - 35, XP027211421, ISSN: 0009-3084, [retrieved on 19970328] *
CLARY L ET AL: "Transmembrane pH-driven Na<+> permeability of fluorinated phospholipid-based membranes", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 51, no. 2-3, 12 February 1998 (1998-02-12), pages 259 - 267, XP004113634, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(97)00179-X *
DR ANDREAS ZUMBÜHL ED - DR ANDREAS ZUMBÜHL: "Synthesis and Applications of Artificial Phospholipids", INTERNET CITATION, 15 December 2010 (2010-12-15), XP002680156, Retrieved from the Internet <URL:http://www.softmattergraduate.uni-freiburg.de/events/e15> [retrieved on 20120809] *
GIORGIO TODD D ET AL: "The effect of bilayer composition on calcium ion transport facilitated by fluid shear stress", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1239, no. 1, 1995, pages 39 - 44, XP002681507, ISSN: 0006-3002 *
HOLME M N ET AL: "Shear stress sensitive nanocontainers for targeted drug delivery", EUROPEAN CELLS AND MATERIALS 2011 SWISS SOCIETY FOR BIOMATERIALS CHE, vol. 22, no. SUPPL.4, 2011, pages 35, XP002681509, ISSN: 1473-2262 *
ILLYA A FEDOTENKO ET AL: "The synthesis of 1,3-diamidophospholipids", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 51, no. 41, 23 July 2010 (2010-07-23), pages 5382 - 5384, XP028239944, ISSN: 0040-4039, [retrieved on 20100807], DOI: 10.1016/J.TETLET.2010.07.140 *
MARGARET N. HOLME ET AL: "Shear-stress sensitive lenticular vesicles for targeted drug delivery", NATURE NANOTECHNOLOGY, 1 June 2012 (2012-06-01), XP055033028, ISSN: 1748-3387, DOI: 10.1038/nnano.2012.84 *
MERGEN F ET AL: "Synthesis of 1,3-diacylaminopropan-2-ols and corresponding 2-acyl derivatives as amide isosteres of natural lipids", CHEMISTRY AND PHYSICS OF LIPIDS, LIMERICK, IR, vol. 59, no. 3, 1 October 1991 (1991-10-01), pages 267 - 272, XP025198099, ISSN: 0009-3084, [retrieved on 19911001], DOI: 10.1016/0009-3084(91)90027-9 *
MORRIS ET AL: "The synthesis of novel melphalan derivatives as potential antineoplastic agents", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 32, no. 4, 1 January 1997 (1997-01-01), pages 343 - 349, XP005276600, ISSN: 0223-5234, DOI: 10.1016/S0223-5234(97)89087-3 *
RANDAD R S ET AL: "SYMMETRY-BASED HIV PROTEASE INHIBITORS CONTAINING A HYDROXY BIS-UREA ISOSTERE", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 4, no. 19, 1 January 1994 (1994-01-01), pages 2343 - 2346, XP001180918, ISSN: 0960-894X, DOI: 10.1016/0960-894X(94)85037-2 *
SHEIKH MOHAMMAD ET AL: "In vitro lipofection with novel series of symmetric 1,3-dialkoylamidopropane-based cationic surfactants containing single primary and tertiary amine polar head groups", CHEMISTRY AND PHYSICS OF LIPIDS, LIMERICK, IR, vol. 124, no. 1, 2003, pages 49 - 61, XP002680154, ISSN: 0009-3084 *
YOSHIIZUMI KAZUYA ET AL: "Studies on scavenger receptor inhibitors. Part 1: synthesis and structure-activity relationships of novel derivatives of sulfatides", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 10, no. 8, 1 January 2002 (2002-01-01), pages 2445 - 2460, XP008092387, ISSN: 0968-0896, DOI: 10.1016/S0968-0896(02)00120-7 *

Also Published As

Publication number Publication date
WO2012119781A2 (en) 2012-09-13
WO2012119780A2 (en) 2012-09-13
WO2012119780A3 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
WO2012119781A3 (en) Novel lipids, phospholipids, phospholipid and lipid compositions and their use
MX2013002603A (en) Oil composition and method for producing the same.
WO2009149418A3 (en) Compositions for the in vivo delivery of rnai agents
WO2011143242A3 (en) Fragrant formulations, methods of manufacture thereof and articles comprising the same
WO2008129358A8 (en) Oil producing microbes and methods of modification thereof
HK1199739A1 (en) Algal lipid compositions and methods of preparing and utilizing the same
NZ708558A (en) Preparation of poly alpha-1,3-glucan esters and films therefrom
WO2012170889A8 (en) Cleavable lipids
BR112013000244A2 (en) lipid liposomes having advantageous pka for administration of rna
WO2012153338A3 (en) Liposomes comprising polymer-conjugated lipids and related uses
MY188956A (en) Processes for producing lipids
EP2581098A3 (en) Customised composition and uses thereof
WO2013033438A3 (en) Nanoparticle peg modification with h-phosphonates
WO2009117316A3 (en) Pharmaceutical compositions having desirable bioavailability
JP2008184431A5 (en)
BR112015022415A2 (en) Liposomal cisplatin compositions for cancer therapy
WO2014057362A3 (en) Omega -3 compositions
WO2013022922A3 (en) Fibrous structures
NZ747847A (en) Lipid compositions
BR112014032759A2 (en) racecadotril lipid compositions
BR112012027550A2 (en) use of a composition
WO2013007637A3 (en) Cosmetic compositions in the form of water-in-oil emulsions including a jasmonic acid derivative and a silicone surfactant
WO2014089511A3 (en) Administering compositions comprising docosapentaenoic acid
WO2011143271A3 (en) Therapeutic liposomes and methods for producing and using the same
WO2011009851A3 (en) Walnut extracts for nutraceutical applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12711343

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12711343

Country of ref document: EP

Kind code of ref document: A2